Asimov Press • 754 implied HN points • 11 Mar 26
- AI models now let researchers design antibody binders on the computer, greatly reducing the experimental search effort needed to find promising candidates.
- There is a practical five-step pipeline — pick a target, prepare or predict its structure, run design tools, filter candidates, and validate in the lab — which uses public tools but typically costs thousands of dollars.
- Design success is highly target-dependent and improving affinity, specificity, and drug-like properties remains difficult and costly, but AI makes it realistic to engineer more complex, multi-property binders going forward.